Newspaper Publication of Audited Financial Result for the quarter and year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Limited (Scrip Code: 531592) has published its audited standalone and consolidated financial results for Q4 FY25 and the full year ended March 31, 2025 in two newspapers — Active Times (English) and Mumbai Lakshadeep (Marathi) on May 23, 2025. The disclosure was made under SEBI's Listing Obligations and Disclosure Requirements (Regulations 30 and 47), as a routine compliance step after filing the detailed results with stock exchanges. From the consolidated extract, the company reported a Q4 FY25 net loss after tax of approximately ₹270.09 lakhs, compared to a profit of about ₹79.77 lakhs in the preceding quarter. Full-year consolidated total comprehensive income stood at roughly ₹744.7 lakhs (FY25) versus a loss of ₹652.97 lakhs in FY24, indicating a turnaround at the yearly level. The filing was signed by Mr. Sohan Chaturvedi, Whole-time Director & CFO.
This is a routine regulatory compliance announcement and does not contain new material information beyond what has already been filed with the stock exchanges. Investors should refer to the full audited results on the BSE and company websites for detailed analysis.